OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Appel on the Significance of International Childhood Cancer Day

February 15th 2024

Burton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

February 15th 2024

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Dr Mikhael on Research Developments in Multiple Myeloma

February 15th 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

Dr Choi on the Implications of Approving Liso-Cel in Patients With CLL

February 15th 2024

Michael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

February 15th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Dr Nguyen on Trimodal Therapy in MIBC

February 15th 2024

Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Dotan on the Use of Geriatric Assessments to Identify Unique Challenges in GI Cancer

February 15th 2024

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Dr Zhang on the Implications of Findings From the KEYNOTE-564 Trial in RCC

February 14th 2024

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Dr Hagensee on Strategies For Cervical Cancer Prevention

February 14th 2024

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

Dr Cohen on Available Treatments For MCL

February 14th 2024

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

February 14th 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Dr Advani on the Advantages of Liquid Biopsy in Metastatic Breast Cancer

February 14th 2024

Pooja Advani, MBBS, MD, discusses the advantages of using liquid biopsy in metastatic breast cancer.

Dr Tripathi on the Use of Frontline Nivolumab/Chemotherapy in Urothelial Carcinoma

February 13th 2024

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma

February 13th 2024

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Dr Kim on the Background of a Real-World Study of the Use of Regorafenib in mCRC

February 13th 2024

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.

Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast Cancer

February 13th 2024

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

February 13th 2024

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Dr Wainberg on the FDA Approval of NALIRIFOX in mPDAC

February 13th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

February 13th 2024

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Dr Feldman on the Background of the TRANSCEND CLL 004 Trial in CLL/SLL

February 13th 2024

Tatyana Feldman, MD, discusses the launch of the TRANSCEND CLL 004 trial in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.